Trial Profile
A Phase II Trial With Radiotherapy Plus Cetuximab to Evaluate Specific Survival Free of Laryngectomy in Patients With Resectable and Locally Advanced Larynx Cancer, After Treatment With TPF.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 May 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin; Docetaxel; Fluorouracil
- Indications Laryngeal cancer
- Focus Therapeutic Use
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 Status changed from recruiting to completed, according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 Primary endpoint has been met. (Specific survival) according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.